Monitoring collagen degradation in patients with arthritis: The search for suitable surrogates

Arthritis and Rheumatism

Volumn 39, Issue 9, 1996, Pages 1455-1465

  Greenwald, Robert A ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGENASE; CYTIDINE TRIPHOSPHATE; DEOXYPYRIDINOLINE; METALLOPROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIDINOLINE;

ARTHRITIS; COLLAGEN DEGRADATION; CROSS LINKING; HUMAN; NONHUMAN; OSTEOARTHRITIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0029788876     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390904     Document Type: Review

References (79)

1. Greenwald RA: Guidelines for clinical trial design for evaluation of matrix metalloproteinase inhibitors: proceedings of a clinical round table discussion. Ann N Y Acad Sci 732:273-279, 1994
2. Jimenez S: Collagen and elastin. In, Primer on the Rheumatic Diseases. Tenth Edition. Edited by HR Schumacher Jr. Atlanta, Arthritis Foundation, 1993
3. Mayne R, Brewton RG: Extracellular matrix of cartilage: collagen. In, Joint Cartilage Degradation. Edited by JF Woessner. DS Howell. New York, Marcel Dekker, 1994
4. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD: Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone 8:87-96, 1990
5. Vincenti MP, Clark IM, Brinckerhoff CE: Using inhibitors of metalloproteinases to treat arthritis: easier said than done? Arthritis Rheum 37:1115-1126, 1994
6. Brandt KD: Toward pharmacologic modification of joint damage in osteoarthritis. Ann Intern Med 122:874-875, 1995
7. Cawston T: Blocking cartilage destruction with metalloproteinase inhibitors: a valid therapeutic target? Ann Rheum Dis 52:769-770, 1993
8. Docherty AJP, O'Connell J, Crabbe T, Angal S, Murphy G: The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotech 10:200-207, 1992
9. Uebelhart D, Delmas PD: Le dosage des molecules de pontage du collagene (pyridinolines) dans l'etude de la degradation du tissu osseux et du cartilage articulaire. Pathol Biol (Paris) 41:951-961, 1993
10. Pasquali M. Still MJ, Dembure PP, Elsas LJ: Pyridinium crosslinks in heritable disorders of collagen. Am J Hum Genet 57:1508-1510, 1995
11. Seibel MJ, Robins SP, Bilezikian JP: Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Mctab 3:263-270, 1991
12. Risteli L, Risteli J, Moniz C: Measuring collagen degradation. Eur J Clin Invest 23:339-340, 1993
13. Hashimoto K, Nozaki M, Yokoyama M, Sano M, Nakano H: Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone rsorption. Maturitas (Limerick) 18:135-142, 1994
14. Garnero P, Shih WJ, Gineyts E, Karpf DB, Dalmas PD: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700, 1994
15. Eyre DR: The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 66 (suppl 266):166-170, 1995
16. Robins SP, Seibel MJ, McLaren AM: Collagen markers in urine in human arthritis. In, Methods in Cartilage Research. Edited by A Maroudas, K Kuettner. San Diego, Academic Press, 1990
17. Peel N, Al-dehaimi A, Colwell A, Russell G, Eastell R: Sulfasalazine may interfere with HPLC assay of urinary pyridinium crosslinks. Clin Chem 40:167-168, 1994
18. Kim M, Otsuka M, Arakawa N: Age related changes in the pyridinoline content of guinea pig cartilage and Achilles tendon collagen. J Nutr Sci Vitaminol (Tokyo) 40:95-103, 1994
19. Frank C, McDonald D, Wilson J, Eyre D, Shrive N: Rabbit medial collateral ligament scar weakness is associated with decreased collagen pyridinoline crosslink density. J Orthop Res 13:157-165, 1995
20. Larbre JP, Da Silva JAP, Moore AR, James LT, Scott DL, Willoughby DA: Cartilage contribution to gender differences in joint disease progression: a study with rat articular cartilage. Clin Exp Rheumatol 12:401-408, 1994
21. Black D, Farquharson C, Robins SP: Excretion of pyridinium crosslinks of collagen in ovariectomized rats as urinary markers for increased bone resorption. Calcif Tissue Int 44:343-347, 1989
22. Tordjman C, Lhumeau A, Pastoureau P, Meunier F, Serkiz B, Voiland JP, Bonnet J: Evaluation and comparison or urinary pyridinium crosslinks in two rat models of bone loss - ovariectomy and adjuvant polyarthritis - using a new automated HPLC method. Bone 26:155-167, 1994
23. Preedy VR, Sherwood RA, Akpoguma CIO, Black D: The urinary excretion of the collagen degradation markers pyridinoline and deoxypyridinoline in an experimental rat model of alcoholic bone disease. Alcohol Alcohol 26:191-198, 1991
24. Jerome CP, Colwell A, Eastell R, Russell GG, Trechsel U: The effect of rat parathyroid hormone (1-34) infusion on urinary 3-hydroxypyridinium cross-link excretion in the rat. Bone 19:117-125, 1992
25. Uebelhart D, Thonar EJ, Pietryla DW, Williams JM: Elevation in urinary levels of pyridinium crosslinks of collagen following chymopapain induced degradation of articular cartilage in the rabbit knee provides evidence of metabolic changes in bone. Osteoarthritis Cartilage 1:185-192, 1992
26. Pokharna HK, Monnier V, Boja B, Moskowitz RW: Lysyl oxidase and Maillard reaction mediated crosslinks in aging and osteoarlhritic rabbit cartilage. J Orthop Res 13:13-21, 1995
27. Oxlund H, Barckman M, Ortoff G, Andreassen TT: Reduced concentrations of collagen crosslinks are associated with reduced strength of bone. Bone 17 (suppl 4):365S-371S, 1995
28. Greenwald RA: Treatment of destructive arthritic disorders with MMP inhibitors: potential role of tetracyclines. Ann N Y Acad Sci 732:181-198, 1994
29. Ganu V, Doughty J, Spirito S, Goldberg R: Elevation of urinary pyridinoline in adjuvant arthritic rats and its inhibition by doxycycline. Ann N Y Acad Sci 732:416-418, 1994
30. Robins SP, Stewart P, Astbury C, Bird HA: Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. Ann Rheum Dis 45:969-973, 1986
31. Black D, Marabani M, Sturrock RD, Robins SP: Urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 48:641-644, 1989
32. Siebel MJ, Duncan A, Robins SP: Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 16:964-970, 1989
33. James IT, Hall GM, Thompson PW, Perrett D, Spector TD: Increased levels of urinary collagen cross links in females with rheumatoid arthritis. Br J Rheumatol 31:27, 1992
34. Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ: Increased levels of urinary collagen cross links in females with rheumatoid arthritis. Clin Rheumatol 12:240-244, 1993
35. Takahashi M, Kushida K, Inoue T: Receiver operating characteristic analysis of urinary pyridinium crosslinks in arthritis. Br J Rheumatol 34:792-793, 1995
36. Sinigaglia L, Varenna M, Binelli L, Bartucci F, Arrigoni M, Ferrara R, Abbiati G: Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 54:144-147, 1995
37. Takahashi M, Kushida K, Ohishi T, Kawana K, Hoshino H, Uchiyama A, Inoue T: Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 37:724-728, 1994
38. Miossec P, Chomarat P, Dechanet J, Moreau J-F, Roux J-P, Delmas P, Banchereau J: Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum 37:1715-1722, 1994
39. Astbury C, Bird HA, McLaren AM, Robins SP: Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Br J Rheumatol 33:11-15, 1994
40. Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P: Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 53:14-17, 1994
41. Kollerup G, Hansen M, Hørslev-Petersen K: Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis: relation to disease activity and effects of methylprednisolone. Br J Rheumatol 33:816-820, 1994
42. Marhoffer W, Stracke H, Masoud I, Scheja M, Graef V, Bolten W, Federlin K: Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 54: 556-559, 1995
43. Thompson PW, Spector TD, James IT, Henderson E, Hart DJ: Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. Br J Rheumatol 31:759-761, 1992
44. MacDonald AG, McHenry P, Robins SP, Reid DM: Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis. Br J Rheumatol 33:16-19, 1994
45. Ricard-Blum S, Chevalier X, Grimaud JA, Larget-Piet B, Uebelhart D: Detectable levels of pyridinoline are present in synovial fluid from various patients with knee effusion: preliminary results. Eur J Clin Invest 25:438-441, 1995
46. Withold W, Georgescu G, Khakzad H, Vosberg H, Mueller-Gaertner HW, Reinauer H: Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases. Clin Biochem 28:511-517, 1995
47. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL: Collagen crosslink metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 151:909-913, 1994
48. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR: A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258, 1992
49. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chestnut CH, Eyre DR: Monitoring bone resorption in early post menopausal women by an immunoassay for cross linked collagen peptides in urine. J Bone Miner Res 9:135-142, 1994
50. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL: Specificity of urinary excretion of cross linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29, 1994
51. Sone T, Miyake M, Takeda N, Fukunaga M: Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults. Bone 17:335-339, 1995
52. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A: Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41:1489-1494, 1995
53. Brenner RE, Vetter U, Bollen AM, Morike M, Eyre DR: Bone resorption assessed by immunoassay or urinary cross linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 9:993-997, 1994
54. Garnero P, Gineyts E, Riou JP, Delmas PD: Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785, 1994
55. Bonde M, Qvist P, Fiedelius C, Riis BJ, Christiansen C: Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025, 1994
56. Silsand T, Reine A, Dugal S, Lunde T, Smedsrudi B, Seeberg T: Urinary concentration of a specific peptide of type I collagen of bone (CrossLaps): correlation to hydroxyproline. Scand J Clin Lab Invest 55:187-193, 1995
57. Hall GM, Spector TD, Delmas PD: Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 38:902-906, 1995
58. Risteli J, Elomas I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxy terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635-640, 1993
59. Hassager C, Jensen LT, Podenphant J, Thomsen K, Christiansen C: The carboxy terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 54:30-33, 1994
60. Scariano JK, Walter EA, Glew RH, Hollis BW, Henry A, Ocheke I, Isichei CO: Serum levels of the pyridinoline crosslinked carboxy terminal telopeptide of type I collagen (ICTP) and osteocalcin in rachitic children in Nigeria. Clin Biochem 28:541-545, 1995
61. Lems WE, Jacobs JWG, van den Brink HR, van Rijn HJM, Bijlsma JWJ: Transient decrease in osteocalcin and markers of type I collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis. Br J Rheumatol 32:787-789, 1993
62. Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J: Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 33:1012-1016, 1994
63. Hakala M, Åman S, Luukkainen R, Risteli L, Kauppi M, Nieminen P, Risteli J: Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis 54:886-890, 1995
64. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J: Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 52:866-869, 1993
65. Kotaniemi A, Isomäki H, Hakala M, Risteli L, Risteli J: Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol 21:1593-1596, 1994
66. Åman S, Hakala M, Risteli L, Risteli J: Increased type I collagen degradation is associated with a need for total joint replacement surgery in rheumatoid arthritis (letter). Ann Rheum Dis 55:147, 1996
67. Giannobile WV, Lynch SE, Denmark RG, Paquette DW, Fiorellini JP, Williams RC: Crevicular fluid osteocalcin and pyridinoline cross-linked carboxy terminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. J Clin Periodontol 21:903-910, 1995
68. Talonpoika JT, Hamalainen MM: Type I collagen carboxy terminal telopeptide in human gingival crevicular fluid in different clinical conditions and after periodontal treatment. J Clin Periodontol 21:320-326, 1994
69. Giannobile W, Lynch S, Denmark R, Paquette D, Williams RC: Crevicular fluid ICTP as an indicator of active bone loss in periodontitis (abstract). J Dent Res 74:172, 1995
70. Shibutani T, Imay K, Furusawa Y, Habuchy N: Deoxypyridinoline as a marker for alveolar bone resorption in periodontitis. J Dent Res 74:528, 1995
71. Kylmala T, Tammela T, Risteli L, Kontturi M. Ilomaa I: Evaluation of the effect of oral codronate on skeletal metastases with type I collagen metabolites: a controlled trial of the Finnish prostate cancer group. Eur J Cancer 29A:821-825, 1993
72. Zucker S, Lysik RM, Zarrabi MH, Greenwald RA, Gruber B, Tickle S, Docherty AJ: Elevated plasma stromelysin levels in arthritis. J Rheumatol 21:2329-2333, 1994
73. Firestein GS, Paine MM, Boyle DL: Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial collagenase gene expression. Arthritis Rheum 37:193-200, 1994
74. Dodge GR, Pidoux I, Poole AR: The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study. Matrix Biol 11:330-338, 1991
75. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, Poole AR: Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 93:1722-1732, 1994
76. Risteli J, Risteli L: Analysing connective tissue metabolites in human serum: biochemical, physiological and methodological as-pects. J Hepatol 22 (suppl 2):77-81, 1995
77. Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I: Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine. Ann Rheum Dis 47:116-126, 1988
78. Greenwald RA: Tetracyclines may be beneficial for rheumatoid arthritis, but not for the reasons that you think. J Clin Rheumatol 1:185-189, 1995
79. Leung MK, Greenwald RA, Ramamurthy NS, Moak SA, Koszulinski R, Dieudonne D, Golub LM: Tenidap and flurbiprofen enhance uptake of matrix metalloproteinase inhibitor 4-dedimethylaminotetracycline in inflamed joints of adjuvant arthritic rats. J Rheumatol 22:1726-1731, 1995